Tailoring active compounds across biological membranes by cubosomal technology: an updated review

doi:10.5246/jcps.2013.04.044

摘要/Abstract

摘要：

It is challenging for many drugs to be transported across various biological membranes. Furthermore, development of many drugs gets thwarted owing to their hydrophilic nature. The bioavailability of such drugs, which is the function of their ability to cross the membrane, tends to be low and exhibit high intra and inter subject variability. At present, formulation scientists are pursuing many projects for transdermal, nasal, target delivery of many active compounds, and it is prudent to explore alternative possibilities. Cubosomes offer transportation and tailoring of active compounds intended for both systemic and dermal delivery. Cubosomes are dispersed, self-assembled nanoparticles of bicontinuous cubic liquid crystalline phase formed from lipid and surfactant systems. Monoolein, poloxamer 407 and polyvinyl alcohol are the mostly used ingredients in the formulation of cubosomes. The adjustment in lipid composition can control the internal and structural changes of cubosomes. Based on the nodal surfaces, three structures of cubosomes proposed are Pn3m, Ia3d and Im3m. Top-down and bottom-up techniques are widely considered in the formulation process of extreme viscous bulk phase and aggregate from a precursor respectively. This article gives a bird’s eye view about the engineering, characterization and evaluation of cubosomes, covering researches and applications of cubosomes done till date.

关键词: Cubosomes, Liquid crystal, Phase transition, Cryo-TEM, Birefringent

Abstract:

Key words: Cubosomes, Liquid crystal, Phase transition, Cryo-TEM, Birefringent

中图分类号:

R943

Supporting: ^*Corresponding author. Tel.: 0091-9010055004; Fax: 0091-8682-247910

Vinod K.R.^*, Sravya K., Sandhya S., David Banji, Anbazhagan S., Prameela Rani A.. Tailoring active compounds across biological membranes by cubosomal technology: an updated review[J]. , DOI: 10.5246/jcps.2013.04.044.

参考文献

[1] Shah, J.C.; Sadhale, Y.; Chilukuri, D.M. Adv. Drug Deliv. Rev. 2001, 47, 229-250.
[2] Borne, J.; Nylander, T.; Khan, A. J. Phys. Chem. B. 2002, 106, 10492-10500.
[3] Patton, J.S.; Carey, M.C. Science. 1979, 204, 145-148.
[4] Patton, J.S.; Vetter, R.D.; Hamosh, M.; Borgstrom, B.; Lindstrom, M.; Carey, M.C. Food Microstruct. 1985, 4, 29-41.
[5] Longer, M.; Tyle, P.; Mauger, J.W. Drug Dev. Ind. Pharm. 1996, 22, 603-608.
[6] Caboi, F.; Nylander, T.; Razumas, V.; Talaikyte, Z.; Monduzzi, M.; Larsson, K. Langmuir. 1997, 13, 5476-5483.
[7] Nylander, T.; Mattison, C.; Razumas, V.; Miezis, Y.; Hakansson, B. Colloids Surf. A. 1996, 114, 311-320.
[8] Spicer, P.T. Cubosomes: Bicontinuous Cubic Liquid Crystalline Nanostructured Particles, in Encyclopedia of Nanoscience and Nanotechnology (Schwarz, J.A.; Contescu, C.; Putyera K. Eds.), New York: Marcel Dekker, 2003, 881-892.
[9] Scriven, L.E. Nature. 1976, 263, 123-125.
[10] Wyatt, D.M.; Dorschel, D. Pharm. Tech. 1992, 16, 116-130.
[11] Clogston, J.; Craciun, G.; Hart, D.J.; Caffrey, M. J. Control. Release. 2005, 102, 441-461.
[12] Nielsen, L.S.; Schubert, L.; Hansen, J. Eur. J. Pharm. Sci. 1998, 6, 231-239.
[13] Drummond, C.J.; Fong, C. Curr. Opin. Colloid Interface Sci. 1999, 4, 449-456.
[14] Brahmankar, D.M.; Jaiswal, S.B. Biopharm. Pharmacokin.-A Treatise. 2^nd ed. Delhi: Vallabh Prakashan. 2005, 305-314.
[15] Venkateswarlu, V. Biopharm. Pharmacokin. Hyderabad: Pharma Book Syndicate. 2005, 283-307.
[16] Sinha, V.R.; Kaur, M.P. Drug Dev. Ind. Pharm. 2000, 26, 1131-1140.
[17] Ankush Shembale, I.; Dipak Borole, K.; Rajesh Lohiya, T. Int. J. Pharm. Res. Dev. 2012, 2, 1-6.
[18] Gustafsson, J.; Ljusberg-Wahren, H.; Almgren, M.; Larsson, K. Langmuir. 1996, 12, 4611-4613.
[19] Gustafsson, J.; Ljusberg-Wahren, H.; Almgren, M.; Larsson, K. Langmuir. 1997, 13, 6964-6971.
[20] Landh, T. J. Phys. Chem. 1994, 98, 8453-8467.
[21] Spicer, P.T.; Lynch, M.L.; Hoath, S.B.; Visscher, M.O. Bicontinuous Cubic Liquid Crystalline Phase and Cubosome Personal Care Delivery Systems, in Delivery System Handbook for Personal Care and Cosmetic Products: Technology, Applications and Formulations (Rosen, M.R. Ed.), New York: William Andrew, 2005, 603-620.
[22] Garg, G.; Saraf, S.; Saraf, S. Biol. Pharm. Bull. 2007, 30, 350-353.
[23] Luzzati, V.; Tardieu, A.; Gulik-Krzywicki, T.; Rivas, E.; Reiss-Husson, F. Nature. 1968, 220, 485-488.
[24] Larsson, K. Nature. 1983, 304, 664-665.
[25] Hyde, S.T.; Andersson, S.; Ericsson, B.; Larsson, K. Z. Kristallogr. 1984, 168, 213-219.
[26] Buchheim, W.; Larsson, K. J. Colloid Interface Sci. 1987, 117, 582-583.
[27] Anderson, D.M.; Wennerstrom, H. J. Phys. Chem. 1990, 94, 8683-8694.
[28] Lawrence, M.J. Chem. Soc. Rev. 1994, 23, 417-424.
[29] Spicer, P.T.; Hayden, K.L.; Lynch, M.L.; Ofori-Boateng, A.; Burns, J.L. Langmuir. 2001, 17, 5748-5756.
[30] Boyd, B.J.; Whittaker, D.V.; Khoob, S.M.; Davey, G. Int. J. Pharm. 2006, 318, 154-162.
[31] Yaghmur, A.; Glatter, O. Adv. Colloid Interface Sci. 2009, 147, 333-342.
[32] Amar-Yuli, I.; Libster, D.; Aserin, A.; Garti, N. Curr. Opin. Colloid Interface Sci. 2009, 14, 21-32.
[33] Leesajakul, W.; Nakano, M.; Taniguchi, A.; Handa, T. Colloids Surf. B. 2004, 34, 253-258.
[34] Worle, G.; Siekmann, B.; Michel Kochc, H.J.; Bunjes, H. Eur. J. Pharm. Sci. 2006, 27, 44-53.
[35] Shen, H.; Crowston, J.G.; Huber, F.; Saubern, S.; McLean, K.M.; Hartley P.G. Biomaterials. 2010, 31, 9473-9481.
[36] Zeng, N.; Hu, Q.; Liu, Z.; Gao, X.; Hu, R.; Song, Q.; Gu, G.; Xia, H.; Yao, L.; Pang, Z.; Jiang, X.; Chen, J.; Fang, L. Int. J. Pharm. 2012, 424, 58-66.
[37] Bei, D. Master of Science. A Thesis in Pharmaceutical Science, University of Missouri-Kansas City. 2009.
[38] Andersson, S.; Jacob, M.; Ladin, S.; Larsson, K. Z. Kristallogr. 1995, 210, 315-318.
[39] Fontell, K.; Mandell, L.; Ekwall, P. Acta Chem. Scand. 1968, 22, 3209-3223.
[40] Lutton, E.S. J. Am. Oil Chem. Soc. 1965, 42, 1068-1070.
[41] Fraser, S.; Separovic, F.; Polyzos, A. Eur. Biophys. J. 2009, 39, 83-90.
[42] Madhurilatha, T.; Srivalli Kumari, P.; Suria Prabha, K. Int. J. Pharm. Res. Clin. 2011, 1, 535-541.
[43] Strom, P.; Anderson, D.M. Langmuir. 1992, 8, 691-709.
[44] Lynch, M.L.; Kochvar, K.K.; Burns, J.L.; Laughlin, R.G. Langmuir. 2000, 16, 3537-3542.
[45] Engstrom, S.; Lindahl, L.; Wallin, R.; Engblom, J. Int. J. Pharm. 1992, 86, 137-145.
[46] Engstrom, S.; Larsson, K.; Lindman, B. Control. Rel. Bioact. Mater. 1998, 15, 105-106.
[47] Engstrom, S.; Norden, T.P.; Nyquist, H. Eur. J. Pharm. Sci. 1999, 8, 243-254.
[48] http://www.chemicalbook.com/ChemicalProductProperty_ EN_CB2757258.htm
[49] Kulkarni, C.V.; Wachter, W.; Iglesias-Salto, G.; Engelskirchen, S.; Ahualli, S. Phys. Chem. Chem. Phys. 2011, 13, 3004-3021.
[50] Abraham, T.; Hato, M.; Hirai, M. Colloids Surf. B. 2004, 35, 107-117.
[51] http://en.wikipedia.org/wiki/Poloxamer_407
[52] Dumortier, G.; Grossiord, J.L.; Agnely, F.; Chaumeil, J.C. Pharm. Res. 2006, 23, 2709-2728.
[53] Ljusberg-Wahren, H.; Nyberg, L.; Larsson, K. Chim. Oggi. 1996, 14, 40-43.
[54] Spicer, P.T. Chem. Eng. Res. Des. 2005, 83, 1283-1286.
[55] Worle, G.; Drechsler, M.; Koch, M.H.J.; Siekmann, B.; Westesen, K.; Bunjes, H. Int. J. Pharm. 2007, 329, 150-157.
[56] Salentinig, S.; Yaghmur, A.; Guillot, S.; Glatter, O. J. Colloid. Interface Sci. 2008, 326, 211-220.
[57] Almgren, M.; Edwards, K.; Gustafsson, J. Curr. Opin. Colloid. Interface Sci. 1996, 1, 270-278.
[58] Mezzenga, R.; Meyer, C.; Servais, C.; Romoscanu, A.I.; Sagalowicz, L.; Hayward, R.C. Langmuir. 2005, 21, 3322-3333.
[59] Rosen, M.R. Delivery System Handbook for Personal Care and Cosmetic Products: Technology, Applications, and Formulations. New York: William Andrew. 2006, 630-647.
[60] Spicer, P.T.; Small, W.B.; Lynch, M.L.; Burns, J.L. J. Nanopart. Res. 2002, 4, 297-311.
[61] Wu, H.; Li, J.; Zhang, Q.; Yan, X.; Guo, L.; Gao, X.; Qiu, M.; Jiang, X.; Lai, R.; Chen, H. Eur. J. Pharm. Biopharm. 2011, 80, 368-378.
[62] Rizwan, S.B.; Dong, Y.D.; Boyd, B.J.; Rades, T.; Hook, S. Micron. 2007, 38, 478-485.
[63] Boyd, B.J. Int. J. Pharm. 2003, 260, 239-247.
[64] Moebus, K.; Siepmann, J.; Bodmeier, R. J. Control. Rel. 2011, 409, 89-95.
[65] Kojarunchitt, T.; Hook, S.; Rizwan, S.; Rades, T.; Baldursdottir, S. Int. J. Pharm. 2011, 408, 20-26.
[66] Kwon, T.K.; Hong, S.K.; Kim, J.C. J. Ind. Eng. Chem. 2012, 18, 563-567.
[67] Kwon, T.K.; Kim, J.C. Int. J. Pharm. 2010, 392, 268-273.
[68] Guillot, S.; Tomsic, M.; Sagalowicz, L.; Leser, M.E.; Glatter, O. J. Colloid Interface Sci. 2009, 330, 175-179.
[69] Esposito, E.; Mariani, P.; Ravani, L.; Contado, C.; Volta, M.; Bido, S.; Drechsler, M.; Mazzoni, S.; Menegatti, E.; Morari, M.; Cortesi, R. Eur. J. Pharm. Biopharm. 2011, 80, 306-314.
[70] Muller, F.; Salonen, A.; Glatter, O. J. Colloid. Interface Sci. 2010, 342, 392-398.
[71] Siekmann, B.; Bunjes, H.; Koch, M.H.J.; Westesen, K. Int. J. Pharm. 2002, 244, 33-43.
[72] Rizwan, S.B.; Assmus, D.; Boehnke, A; Hanley, T.; Boyd, B.J.; Rades, T.; Hook, S. Eur. J. Pharm. Biopharm. 2011, 79, 15-22.
[73] Gan, L.; Han, S.; Shen, J.; Zhu, J.; Zhu, C.; Zhang, X.; Gan, Y. Int. J. Pharm. 2010, 396, 179-187.
[74] Esposito, E.; Cortesi, R.; Drechsler, M.; Paccamiccio, L.; Mariani, P.; Contado, C.; Stellin, E.; Menegatti, E.; Bonina, F.; Puglia, C. Pharm. Res. 2005, 22, 2163-2173.
[75] Bei, D.; Marszalek, J.; Youan, B.C. AAPS Pharm. Sci. Tech. 2009, 10, 1032-1039.
[76] Lai, J.; Chen, J.; Lu, Y.; Sun, J.; Hu, F.; Yin, Z.; Wu, W. AAPS Pharm. Sci. Tech. 2009, 10, 960-966.
[77] Pitzalis, P.; Monduzzi, M.; Krog, N.; Larsson, H.; Ljusberg-Wahren, H.; Nylander, T. Langmuir. 2000, 16, 6358-6365.
[78] Wang, F.; Hickner, M.; Kim, Y.S.; Zawodzinski, T.A. McGrath, J.E. J. Membr. Sci. 2002, 197, 231-242.
[79] Nguyen, T.H.; Hanley, T.; Porter, C.H.J.; Boyd, B.J. J. Control. Release. 2011, 153, 180-186.
[80] Enriquez, J.; Goldberg, R. “Transforming Life, Transforming Business: the Life-Science Revolution”, Harvard Business Review, 2000, 96-104.
[81] Ribier, A.; Biatry, B. France Eur. Pat. Appl. 1995, 13.
[82] Ribier, A.; Biatry, B. France Eur. Pat. Appl. 968, 704. 1996, 16.
[83] Ribier, A.; Biatry, B. USA. 5, 756, 108. 1998.
[84] Schreiber, J.; Albrecht, H., Hair Care Products with a Content of Disperse Phase Liquid Crystals Which Form Cubic Phases, Ger. Offen. (Beiersdorf AG, Germany) DE (2002a).
[85] Schreiber, J.; Schwarzwaelder, C.; Cassier, T. Skin Care Products with a Content of Disperse Phase Liquid Crystals Which Form Cubic Phases, Ger. Offen. (Beiersdorf AG, Germany) DE (2002).

[86] Afriat, I.; Biatry, B. Use of Cubic Gel Particles as Agents against Pollutants, Especially in a Cosmetic Composition, Eur. Pat. Appl. (L’Oreal, Fr.)., Ep, (2001).
[87] Biatry, B. Use of Phytantriol as Anti-Pollution Agent in a Cosmetic Composition, Eur. Pat. Appl. (L’Oreal, Fr.). Ep, (2001) 1, 161, 938.
[88] Esposito, E.; Carotta, V.; Scabbia, A.; Trombelli, L.; D’Antona, P.; Menegatti, E.; Nastruzzi, C. Int. J. Pharm. 1996, 142, 9-23.